---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011611"
form_type: "8-K"
ticker: "USAQ"
cik: "0000856984"
company_name: "QHSLab, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:50:19.208660+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# QHSLab 2023 revenue up 13% to $1.41M; net loss halved to $(240K)

## Summary
- Revenue of $1,408,995, up from $1,243,186 in 2022, driven by allergy kits and digital medicine subscriptions.
- Gross margin improved to 56.3% from 49.8%; gross profit $793,607.
- Net operating loss reduced to $(240,158) from $(560,539); sales & marketing down to $488,537.
- New EHR partnership connects 160,000 medical professionals; evidence-based PHQ-9/GAD-7 improvements shown.
- R&D spending increased slightly to $214,008 for proprietary platform enhancements.

## SEC filing metadata
- accession: 0001493152-24-011611
- form_type: 8-K
- ticker: USAQ
- cik: 0000856984
- company_name: QHSLab, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/856984/000149315224011611/0001493152-24-011611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/856984/000149315224011611/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011611
- JSON: https://secwatch.observer/filing/0001493152-24-011611.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.